Part I: The Industrialization of Nobel Prize in Physiology or Medicine in the Past Decade

The Nobel Prize in Physiology or Medicine, administered by the Nobel Foundation, is awarded
once a year for outstanding discoveries in the fields of life sciences and medicine. It is one of the
five Nobel Prizes established in 1895 by Swedish chemist Alfred Nobel, the inventor of dynamite,
in his will.

What has Nobel Prize in Physiology or Medicine to do with the life science industry? We may find
an answer from the Prize awarded in the past decade.

2017 Circadian Rhythm

The Nobel Prize in Physiology or Medicine 2017 was awarded jointly to Jeffrey C. Hall, Michael
Rosbash and Michael W. Young "for their discoveries of molecular mechanisms controlling the
circadian rhythm". The winners isolated a special genetic period that controls normal circadian
rhythms, which encodes a protein, PER, that accumulates in cells at night and starts to degrade
during the day. The winners then discovered additional protein components that revealed the clock
mechanism of intracellular self-maintenance and made important breakthroughs in the study of the
clock.

2016 Autophagy

The Nobel Prize in Physiology or Medicine 2016 honored Japanese scientist Yoshinori Ohsumi for
"discovering cellular autophagy." Although humans have had cognition in autophagy for more
than 50 years, the key role and function in the physiology and medical research were not
discovered until the discovery of autophagy by Takuya Yoshinori in the 1990s. Autophagy can
destroy invading bacteria and viruses and is also critical for embryonic development and cell
differentiation. Mutations in the autophagy gene can trigger many diseases. The current
application of this outcome in the industry includes include Parkinson's disease, type 2 diabetes,
cancer and aging. Related research is being carried out closely in order to develop the relevant
target autophagy drugs to treat a variety of diseases.

2015 Parasitic Diseases

The Nobel Prize in Physiology or Medicine 2015 was awarded to Irish scientist William Campbell,
Japanese scientist Omura and Chinese pharmacist Yoyo Tu. Half of this award was awarded to
William Campbell and Omura for recognizing new treatments for roundworm infection (the
discovery of ivermectin and abamectin), and the other half for Yoyo Tu in recognition of her
discovery of new treatment for malaria (the discovery of artemisinin). Ivermectins are now widely
used in the prevention and treatment of gastrointestinal nematodes, lung nematodes and parasitic
arthropods in cattle, sheep, horses, pigs, gastrointestinal nematodes, ear mites, scabies, heartworm
and microfilaria in dogs, as well as poultry gastrointestinal nematodes and ectoparasites.
Avermectin is widely used as agricultural or veterinary Bactericide, insecticide, acaricide.
Artemisinin was developed and used as a new derivative drug to treat cancer, kala-azar, lupus and
other diseases, and new uses are being explored for treating AIDS, cancer, Leishmania,
schistosomula, parasite, toxoplasmosis and detoxification.

About Author

Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services

that cover the full scope of biotechnology needs of early drug discovery and development,
including antibody sequencing, Peptide Mapping, antibody synthesis, etc. As a trusted provider of
the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large
number of satisfied clients from biotechnology and pharmaceutical companies as well as
government and academic research laboratories all over the world.

https://medium.com/@candyjkswift/part-i-the-industrialization-of-nobel-prize-in-physiology-or-m
edicine-in-the-past-decade-5e4382ac25a0